European journal of preventive cardiology
Yes, GLP-1 receptor agonists have demonstrated cardiovascular benefits, such as reducing the risk of heart attack and stroke in individuals with type 2 diabetes and established cardiovascular disease
The remaining 51 records were retrieved in full text for eligibility assessment
The GLP-1 hormone is released naturally after meals and sends signals to the brain that promote fullness, slow down gastric emptying, and help regulate blood sugar levels
By lowering the systemic oxidative burden, NAC helps "rescue" these exhausted immune cells
The June study examined a total of 139,002 patients with diabetes, which included a group of 46,334 patients who had taken GLP-1RAs and a group of 92,668 who had not